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Background:  Cell  culture-derived  inactivated  inﬂuenza  vaccines  (TIVc)  are  necessary  for  scale  and  pre-
dictability of  production  to meet  global  demand.  This  study  compared  the  safety  and  tolerability  of TIVc
with  an  egg-derived  trivalent  inﬂuenza  vaccine  (TIVf)  in  4–17  yearolds.
Methods:  A  Phase  3 observer  blind,  multicenter  study  enrolled  2055  healthy  participants  randomized
2:1  to receive  either  TIVc  or TIVf,  respectively  (1372  TIVc and  683  TIVf  evaluable  subjects).  Participants
received one  dose  each  on  Days  1  and  28  (4–8 year-olds  not  previously  vaccinated  [NPV])  or  one dose
on  Day  1 (4–8  and  9–17  yearolds  previously  vaccinated  [PV]).  Solicited  adverse  events  (AEs) occurring
within  7 days  after  each  vaccination  were  assessed;  participants  were  followed  up  for  6  months  after
their  last dose  for safety.
Results: Most  solicited  and unsolicited  AEs  were mild  to moderate  with  <1%  in  the  severe  category.  No
withdrawals  due  to  AEs,  deaths  or vaccine-related  SAEs  were  reported.  TIVc and  TIVf  were  similar  in
percentages  of participants  reporting  solicited  reactions  in 4–8  years  NPV  group  after  the  1st dose:  local
reactions,  TIVc:  48%, TIVf:  43%;  systemic  reactions,  TIVc:  34%,  TIVf:  32%;  percentages  were  lower  following
the  2nd  dose  in  TIVc;  local  reactions:  TIVc:  40%;  TIVf:  43%;  systemic  reactions:  TIVc:  21%;  TIVf:  22%.  In
4–17  years  PV group,  solicited  reactions  were  lower  following  TIVf,  local  reactions:  TIVc:  53%;  TIVf:  43%;
systemic  reactions:  TIVc:  37%,  TIVf:  30%.  Injection-site  pain  was  the  most  common  solicited  reaction,  and
was  similar  following  TIVc  and  TIVf  in 4–8 yearolds  (TIVc:  56%;  TIVf:  55%),  and  lower  following  TIVf  in
9–17  years  group  (TIVc:  52%;  TIVf:  42%).  Reporting  of unsolicited  AEs  was  similar  for  TIVc  and  TIVf  across
the  two age  groups.
Conclusion:  TIVc  was  well  tolerated  and  had  a safety  and  reactogenicity  proﬁle  similar  to that  of  TIVf  in
healthy 4–17  yearolds  (NCT01857206).
ublis© 2015  The  Authors.  P
. IntroductionThe inﬂuenza virus is a major cause of respiratory infection
nd contributes to substantial mortality and morbidity in children,
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elderly and individuals with concomitant diseases that place them
at greater risk for inﬂuenza-related complications. Young children
are the most infected group amongst all age groups by inﬂuenza
[1]. Vaccination remains the basis of inﬂuenza prevention; how-
ever, the availability of seasonal inﬂuenza vaccines is burdened
by the annual updates to the vaccine content that are necessary
due to antigenic changes in circulating inﬂuenza viruses [2–4]. The
recent experience with pandemic (H1N1) 2009 [5], in which large
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Study vaccines.
TIVc (Flucelvax®) TIVf (Fluvirin®)
Northern
Hemisphere
A/Brisbane/10/2010
(H1N1)
A/Christchurch/16/2010
(H1N1)
A/Texas/50/2012
(H3N2)
A/Texas/50/2012
(H3N2)
B/Massachusetts/2/2012 B/Massachusetts/02/2012
Southern
Hemisphere
A/Brisbane/10/2010
(H1N1)
A/Christchurch/16/2010
(H1N1)
A/Victoria/361/2011
(H3N2)
A/Victoria/361/2011
(H3N2)
B/Wisconsin/1/2010 B/Hubei-
Wujiagang/158/2009
Note: Each 0.5 ml  dose of study vaccine contained approx. 15 g of puriﬁed viralT. Nolan et al. / Vac
upplies of effective vaccine against this newlycirculating strain
ere needed in a rapid manner, emphasized the need for produc-
ion methods that can meet surge demand for vaccines, both with
espect to timing and quantity.
Conventional egg-based inﬂuenza vaccines depend on the trans-
ission of inﬂuenza virus in embryonated chicken eggs, a method
hat has inherent limitations in terms of volume [6]. In particular,
he system of egg-based production is limited by the availability
nd supply of eggs and growth constraints for some viral strains,
s well as manufacturing difﬁculties, such as microbial contam-
nation that can lead to delays in production and deﬁciencies in
upply [7–10]. To address the challenges of conventional egg-based
nﬂuenza vaccines, the World Health Organization (WHO) rec-
mmended, in 1995, using alternative culture systems, such as
stablished mammalian cell lines, for the production of inﬂuenza
accines [11]. To meet increasing demand for large quantities of
accine in a timely manner, cell culture-based vaccine production
ethods are advantageous over conventional egg-based systems
ecause of the relative ease with which they can be rapidly scaled
p, thus providing more substrate for virus growth [12]. Moreover,
ue to the automated manufacturing process, cell culture-based
accine production methods are associated with a lower risk for
ontamination [13].
Among the commercially available vaccines, Flucelvax® is a
easonal trivalent, cell culture-derived, inactivated subunit vac-
ine (TIVc) produced in Madin–Darby Canine Kidney (MDCK) cells.
his vaccine was licensed in the United States for adults in 2012.
hile Optaﬂu® (Novartis Vaccines and Diagnostics GmBH, Mar-
urg Germany) has been approved in Europe since 2007 for use
n individuals aged ≥18 years. Previous clinical trials conducted in
dults and elderly have shown that the vaccine efﬁcacy, immuno-
enicity and safety proﬁles of TIVc are similar to that of egg-based
nﬂuenza vaccines [12,14,15]. The safety and immunogenicity of
IVc has also been evaluated previously in children 3 through 17
ears of age [6]. The current study is intended to expand the safety
atabase in children <18 years of age.
The primary objective of the study presented here was to evalu-
te the safety and tolerability of TIVc, as compared to a conventional
gg-based vaccine, TIVf (Fluvirin®, Novartis Vaccines), in healthy
hildren and adolescents aged 4–17 years.
. Materials and methods
.1. Study design
This Phase 3, observer-blind, randomized, multicenter study
as conducted between May  2013 and June 2014 at multiple study
ites in the Unites States (18 sites), Australia (6 sites), New Zealand
2 sites), the Philippines (5 sites) and Thailand (3 sites). The study
as conducted in accordance with Good Clinical Practice guidelines
nd the Declaration of Helsinki, and was approved by institutional
eview boards or ethics committees in each area. Written informed
onsent was obtained from parents or legal guardians and the
articipant.
.2. Participants
Eligible study participants were healthy 4–17 year-old males
nd females whose parents/legal guardians had provided written
nformed consent and where applicable informed assent was also
btained from subjects. The main exclusion criteria included: history of any serious disease, a history of serious adverse
vent (SAE) from vaccine components, an impaired or altered
mmune function, a history of Guillain–Barré syndrome, a history
f bleeding diathesis, a planned surgery during the study period,hemagglutinin (HA) derived from the tabulated strains based on WHO  strain rec-
ommendations for use in the 2013 Southern Hemisphere, or the 2013/2014 Northern
Hemisphere inﬂuenza season.
laboratory-conﬁrmed inﬂuenza within 6 months before vaccina-
tion, and fever or any acute illness within 3 days before study
vaccination.
A total of 2055 healthy children and adolescents were enrolled
(Fig. 1). Participants were stratiﬁed into two age cohorts, based on
age at enrollment: 4–8 year-olds and 9–17 year-olds. Participants
in the 4–8 years cohort were further stratiﬁed into subsets based
on their inﬂuenza vaccination history (“previously vaccinated” or
“not previously vaccinated”). They were then randomly assigned in
a pre-speciﬁed ratio of 2:1 by an Interactive Response Technology
(IRT) to receive either TIVc or TIVf.
2.3. Vaccines
Each 0.5 ml  dose of the investigational, two subunit inactiv-
ated inﬂuenza vaccines were used in the study: an MDCK cell
culture-derived subunit inﬂuenza vaccine, TIVc [Flucelvax®, Novar-
tis Vaccines GmbH & Co KG, Marburg, Germany] and a conventional
egg-based vaccine, TIVf [Fluvirin®, Novartis Vaccines, Liverpool,
UK].
Details of vaccine antigen composition are provided in Table 1.
TIVc formulations for participants in the Southern and North-
ern Hemispheres were identical apart from the inﬂuenza strains
included in this vaccine. The same applied to TIVf formulations for
Southern and Northern Hemisphere participants. Vaccines were
administered intramuscularly preferably in the deltoid region of
the non-dominant arm by unblinded study staff who did not par-
ticipate in any safety or tolerability assessments.
2.4. Safety assessment
Participants were followed through for safety and tolerabil-
ity up to 6 months following the last vaccine dose. Safety and
reactogenicity assessments included reports of solicited local and
systemic reactions and unsolicited adverse events (AEs). Partici-
pants were observed in the clinic for 30 min  post-vaccination, the
frequency and severity of solicited local and systemic reactions
were recorded on diary cards for 7 days following vaccination
on Day 1. For the 4–8 year-old participants who had not been
previously vaccinated against inﬂuenza, the frequency and sever-
ity of solicited local and systemic reactions were also recorded
on diary cards for 7 days after the second dose was adminis-
tered on Day 29. Solicited local reactions included pain at the
injection site, erythema, induration, swelling and ecchymosis.
Solicited systemic reactions included headache, chills, fatigue,
arthralgia, malaise, myalgia, nausea, sweating, vomiting, diarrhea
and fever. Other indicators of reactogenicity, including body tem-
perature at each time point for 7 days after vaccination and
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he use of analgesics/antipyretic medication for prophylaxis or
reatment, were also collected for 7 days after each vaccina-
ion. Any solicited local and systemic reactions that continued
eyond 7 days post-vaccination were recorded as unsolicited
Es.
For the 4–8 year-old participants who had not been previously
accinated unsolicited AEs were collected from Day 1 through Day
9, whereas SAEs, medically attended AEs and NOCD were collected
ntil study termination i.e. 6 months following the 2nd (last) vac-
ination or Day 213. For the 4–8 year old previously vaccinated
articipants, and all the 9–17 year old participants, unsolicited
Es were collected from Day 1 through Day 28, whereas SAEs,
edically attended AEs and NOCD were collected until study ter-
ination i.e. 6 months after the single (last) vaccination or Day
83.
.5. Study power and analysis
The study was designed to extend the safety database of
he cell-derived vaccine in the pediatric population 4–17 years
f age in order to compile a safety database of at least 3000
accinated participants, complementing the data from an ear-
ier study in which 2100 participants were vaccinated with the
IVc [6]. To meet this requirement, a target of 1359 participants
ere enrolled in the TIVc arm of the current study allowingor a 20% drop out rate. No formal power calculations were
arried out, and no formal hypotheses or inferential tests for
omparisons between the vaccine groups were pre-speciﬁed or
onducted.ow chart.
3. Results
3.1. Participants
A total of 2055 participants were enrolled, 2032 (99%) of which
completed the study (Fig. 1). The overall number of premature
withdrawals was 23 participants and the most common reason for
withdrawal was  loss to follow-up with less than 1% (15/2055). None
of the withdrawals from the study were due to AEs. The baseline
characteristics of enrolled participants were balanced between the
TIVc and TIVf groups. The majority of the enrolled subjects were
Asian followed by the white population (Table 2).
3.2. Safety and tolerability
Of 2055 enrolled participants, 2052 (>99%) received a study vac-
cination and were included in the safety analyses (Fig. 1).
3.3. Solicited reactions
Similar percentages of solicited local reactions were reported
in the NPV 4–8 year-old participants in the TIVc and TIVf groups
following the second vaccination (Table 3). Percentages of partic-
ipants reporting local reactions in the previously vaccinated 4–17
yearolds who  received only a single dose of TIVc was similar to that
observed in the NPV 4–8 yearolds following the ﬁrst vaccine dose.
However, the percentage of participants reporting such reactions
was lower following the ﬁrst dose of TIVc in not previously vacci-
nated children (Table 3). A similar trend was observed for solicited
systemic reactions; TIVc and TIVf were similar in NPV 4–8 year-old
T. Nolan et al. / Vaccine 34 (2016) 230–236 233
Table  2
Summary of demographic characteristics of participants enrolled in the study, by age cohort.
Characteristic 4–8 years 9–17 years
TIVc (n = 690) TIVf (n = 341) TIVc (n = 682) TIVf (n = 342)
Age
Mean (SD), years 5.9 (1.4) 6.0 (1.4) 12.3 (2.3) 12.5 (2.5)
Gender, n (%)
Male 328 (48) 178 (52) 341 (50) 156 (46)
Female  362 (52) 163 (48) 341 (50) 186 (54)
Race,  n (%)
Asian 401 (58) 199 (58) 486 (71) 244 (71)
Black  or African American 17 (2) 11 (3) 3 (<1) 2 (<1)
Native  Hawaiian or other Paciﬁc Islander 0 0 3 (<1) 1 (<1)
Other  14 (2) 4 (1) 16 (2) 9 (3)
White  258 (37) 127 (37) 174 (26) 86 (25)
Ethnicity, n (%)
Hispanic or Latino 21 (3) 7 (2) 4 (<1) 2 (<1)
Not  Hispanic or Latino 667 (97) 333 (98) 676 (99) 340 (99)
Not  Reported/Unknown 2 (<1) 1 (<1) 2 (<1) 0
Previous inﬂuenza vaccination, n (%) 72 (10) 34 (10) 11 (2) 6 (2)
SD: standard deviation.
Table 3
The percentages of participants reporting any solicited reactions within seven days after any vaccination.
4–8 years (NPV)
ﬁrst dose
4–8 years (NPV)
second dose
4–17 years (PV)
single dose
TIVc
(n = 391)
TIVf
(n = 199)
TIVc
(n = 385)
TIVf
(n = 197)
TIVc
(n = 979)
TIVf
(n = 480)
Any (%) 61 63 48 52 63 54
Local  (%) 48 43 40 43 53 43
Systemic (%) 34 32 21 22 37 30
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sig. 2. The percentage of participants who  reported any (severe* in brackets) solic
–17  years, by vaccine group. * Reactions were categorized as mild, moderate or sev
aily  activities, respectively.
articipants after the ﬁrst and second dose, and the percentage
f participants reporting such reactions was lower following the
econd dose; a higher percentage of previously vaccinated 4–17
ear old participants reported solicited systemic reactions follow-
ng TIVc vs. TIVf (Table 3). The percentages of individual solicited
ocal reactions reported are shown in Fig. 2. Most solicited local
eactions were mild to moderate with <1% in the severe cate-
ory. Injection-site pain was the most commonly reported solicited
ocal reaction. Percentage of participants reporting injection-site
ain in the 4–8 year-old age group was similar across the two
accine groups (Fig. 2A); however, a lower percentage of 9–17 year-
ld participants in the TIVf group reported this reaction (Fig. 2B).
eporting of other solicited local reactions was similar for TIVc
nd TIVf across both age groups, though the proportion of partic-
pants reporting such reactions was lower in the older age group
Fig. 2A and B).
The percentages of participants reporting individual solicited
ystemic reactions within 7 days following any vaccination arecal reactions within 7 days of any vaccination in age cohorts (A) 4–8 years and (B)
 they resulted in no limitation of, some limitation of, or inability to perform normal
shown in Fig. 3A and B; the most commonly reported solicited
systemic reactions were, malaise among 4–8 yearolds and
headache among 9–17 yearolds (Fig. 3A). Most solicited systemic
reactions were mild to moderate with less than 1% in the severe
category and percentages of participants reporting these reactions
were in a similar range across the two  vaccine groups (Fig. 3). A
majority of participants had a body temperature within normal
range. Percentage of participants with body temperature >38 ◦C
(fever) was similar across the two vaccine groups among 4–8
yearolds and 9–17 yearolds (Fig. 3). A minority of participants used
analgesics and antipyretics with 13% and 12% in TIVc and TIVf
groups of 4–8 yearolds and with 6% and 5% in TIVc and TIVf groups
of 9–17 yearolds, respectively.3.4. Unsolicited AEs
Unsolicited AEs reported by NPV 4–8 year-old participants were
similar across the two  vaccine groups (Table 4). Upper respiratory
234 T. Nolan et al. / Vaccine 34 (2016) 230–236
Fig. 3. The percentage of participants who reported any (severe* in brackets) solicited systemic reactions occurring within7days of any vaccination in age cohorts of (A) 4–8
years  and (B) 9–17 years, by vaccine group. * Reactions were categorized as mild, moderate or severe, if they resulted in no limitation of, some limitation of, or inability to
perform normal daily activities, respectively.
Table 4
The percentages of participants reporting unsolicited adverse events, by group and age cohort.
4–8 years (NPV)
ﬁrst dose
4–8 years (NPV)
second dose
4–8 years (PV)
single dose
9–17 years (PV)
single dose
TIVc
(n = 391)
TIVf
(n = 199)
TIVc
(n = 391)
TIVf
(n = 199)
TIVc
(n = 297)
TIVf
(n = 141)
TIVc
(n = 681)
TIVf
(n = 341)
Any AE (%) 33 31 19 22 37 35 23 26
At  least possibly related AE (%) 7 6 2 4 5 6 5 6
SAE  (%) 1 1 2 2 3 1 1 3
Medically attended AE (%) 12 11 38 42 40 32 25 31
NOCD (%) 0.3 0 1 2 1 1 0.4 0.3
AE: adverse events, NOCD: new onset chronic diseases, SAE: serious adverse events. For 4–8 year-old participants who were not previously vaccinated against inﬂuenza,
AEs  were collected from Day 1 through 49; SAEs, medically attended AEs and NOCD were collected up to Day 213. For 4–8 year-old participants who  had been previously
vaccinated against inﬂuenza and all 9–17 year-old participants, AEs were collected from Day 1 through Day 28; SAEs, medically attended AEs and NOCD were collected up
to  Day 183.
Table 5
Percentage of participants with unsolicited adverse events by preferred term.
4–8 years (NPV/PV) 9–17 years (PV)
TIVc
(n = 688)
TIVf
(n = 340)
TIVc
(n = 681)
TIVf
(n = 341)
Upper respiratory tract infection (%) 11 12 5 6
Nasopharyngitis (%) 3 3 2 4
Viral  infection (%) 4 3 1 1
Cough (%) 3 4 0.6 0.3
Pyrexia (%) 3 4 0.3 0.6
Headache (%) 1 1 2 1
Vomiting (%) 1 3 1 1
t
(
A
SGastroenteritis (%) 1 
Rhinorrhoea (%) 1 
Oropharyngeal pain (%) 1 ract infection was the most commonly reported unsolicited AE
Table 5). A lower percentage of participants reported unsolicited
Es after the second dose vs. ﬁrst dose in the 4–8 years NPV group.
imilar percentages of participants reported such events following1 1 2
2 0.3 1
2 1 1a single dose of TIVc or TIVf among the PV 4–8 yearolds and 9–17
yearolds who received only a single dose (Table 4). Most of the
unsolicited AEs were mild to moderate in intensity with <1% in the
severe category. Most of these AEs were transient and resolved by
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he study completion. No participant withdrew due to an adverse
eaction.
No deaths or vaccine-related SAEs were reported. A total of
4 participants of both NPV and PV 4–8 years (2% for both vac-
ine groups) and 16 participants of PV 9–17 years (TIVc: 1%; TIVf:
%) experienced SAEs during the study. None of the reported SAEs
ere judged by the investigator as related to the study vaccine.
ost of the reported SAEs were consistent with common inter-
urrent illnesses of childhood. A total of three pregnancies were
onﬁrmed during the course of the study; for two participants
n the TIVf group, the pregnancies terminated as spontaneous
bortion (diagnosed 87 days after the last vaccination), and still-
irth; both outcomes were reported (following completion of the
tudy). The third pregnancy followed normal course, and pro-
ressed to full-term normal delivery without complications. The
ercentages of subjects with medically attended AEs were simi-
ar in the TIVc and TIVf groups with 33% and 36%, respectively.
n general, percentages of subjects who reported unsolicited AEs
ere higher in the US (TIVc: 41%; TIVf: 42%), Australian (TIVc: 50%;
IVf: 43%), and New Zealand (TIVc: 44%; TIVf: 48%) populations
hen compared with subjects in Asian countries (Philippines (TIVc:
4%; TIVf: 26%) and Thailand (TIVc: 24%; TIVf: 29%), respectively.
ost of the medically attended AEs were judged as not related to
he study vaccine. A minority of participants reported new onset
hronic diseases (NOCD), the most common events were attention
eﬁcit/hyperactivity disorder and allergic rhinitis, and similar per-
entages of participants reported these events in the two vaccine
roups (Table 4). All of the reported NOCDs were judged as unre-
ated to the study vaccine. A single case of psoriasis in the TIVf
roup (NPV 4–8 year-old group) was reported as possibly related
s assessed by the investigator due to the temporal relationship
nd lack of clear alternate cause. The event was ongoing at the end
f the study.
. Discussion
This Phase 3 study was conducted to expand upon the safety
atabase of the cell culture-derived TIVc vaccine in a pediatric pop-
lation. The results demonstrated that both vaccines were well
olerated with no withdrawals due to AEs, very few severe or SAEs,
nd no related SAEs. Most of the reported solicited reactions were
ild to moderate in intensity and transient in nature and most
esolved within 7 days after vaccination. Injection-site pain was  the
ost common solicited local reaction, with few (1% or ≤1%) being
n the severe category. The percentage of participants reporting
ain was lower for TIVf group in 9–17 yearolds than that observed
or the TIVf in the 4–8 year PV and NPV or that observed for TIVc
n any of the age groups (4–8 years NPV, 4–8 years PV and 9–17
ears PV). While a somewhat higher percentage of participants
eported solicited systemic reactions following TIVc in the 4–17
ears PV group, most of these reactions were mild or moderate in
everity.
The results of this study demonstrate that TIVc had a safety
nd tolerability proﬁle that was similar to that of TIVf in 4–17
ear-old participants and is consistent with the previous pub-
ished safety and tolerability proﬁle of TIVc in this age group.
n the previous study conducted with TIVc and TIVf in children
–17 years of age, following administration of two  doses of either
IVc or TIVf vaccine in NPV 3–8 year-olds and a single dose of
ither of the vaccine in PV 9–17 year participants, there were no
linically important differences in the frequency, type, or sever-
ty of local and systemic solicited reactions, or in spontaneously
eported AEs and SAEs, between recipients of either the cell-derived
r egg-derived inﬂuenza vaccines within the 6-month follow up
eriod post-vaccination. The rates of AEs observed in children4 (2016) 230–236 235
following TIVc vaccination in the current study are similar to those
reported in the previous study [6]. Also, previous trials with cell
culture-derived inﬂuenza vaccines have demonstrated immuno-
logical non-inferiority, as well as a similar safety and tolerability
proﬁle, when compared to a licensed conventional egg-based TIV
in adult and elderly populations who  received a single dose of either
vaccine [12,14–16].
In conclusion, this study demonstrated that the TIVc, the cell
culture-derived, inactivated subunit inﬂuenza vaccine evaluated
in the study, was  well-tolerated in children and adolescents and
its safety and tolerability proﬁle was similar to that of TIVf, the
conventional egg-based vaccine.
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